Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177520 | 1.00 | PRSS1 (0.41) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| Bromide SCHEMBL16177686 | 0.98 | PRSS1 (0.41) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| SCHEMBL16177434 | 0.98 | PRSS1 (0.39) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| SCHEMBL16177608 | 0.91 | ALDH1A1 (0.39) | CYSLTR2CYSLTR1KCNH2DNM1PPARG | |
| SCHEMBL21251505 | 0.91 | PRSS1 (0.37) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| SCHEMBL28339211 | 0.89 | ESR1 (0.38) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| SCHEMBL15632882 | 0.87 | TSHR (0.47) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| Hydrogen Sulfide SCHEMBL11761591 | 0.86 | TSHR (0.46) | PRSS1PRSS2PRSS3CSNK1ECYSLTR2 | |
| SCHEMBL6679062 | 0.84 | ALDH1A1 (0.50) | KCNH2MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL6684956 | 0.84 | ALDH1A1 (0.50) | KCNH2MEN1KMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989070-B1 | IMPROVED FULLERENE DERIVATIVES AND RELATED MATERIALS, METHODS AND DEVICES | MERCK PATENT GMBH (DE) | 2019-08-14 | — | — | EP | disclosed |
| US-20170098775-A1 | FULLERENE DERIVATIVES, AND RELATED MATERIALS, METHODS AND DEVICES | NANO-C, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170098775-A1 | FULLERENE DERIVATIVES, AND RELATED MATERIALS, METHODS AND DEVICES | NANO-C, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9502658-B2 | Fullerene derivatives and related materials, methods, and devices | NANO-C, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9502658-B2 | Fullerene derivatives and related materials, methods, and devices | NANO-C, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9502658-B2 | Fullerene derivatives and related materials, methods, and devices | NANO-C, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140312281-A1 | FULLERENE DERIVATIVES AND RELATED MATERIALS, METHODS, AND DEVICES | NANO-C, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140312281-A1 | FULLERENE DERIVATIVES AND RELATED MATERIALS, METHODS, AND DEVICES | NANO-C, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140312281-A1 | FULLERENE DERIVATIVES AND RELATED MATERIALS, METHODS, AND DEVICES | NANO-C, INC. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170098775-A1 | FULLERENE DERIVATIVES, AND RELATED MATERIALS, METHODS AND DEVICES | PPOX, OCIAD2, OCIAD1 | PRSS1 4654/4885PRSS2 4462/4885PRSS3 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.